Table 3 from TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden–High Tumors
收藏数据链接：
官方服务：
资源简介：
Summary of IRC- and INV-assessed efficacy by most common (≥7 patients) tumor type in patients with TMB ≥13 mut/Mb per the enrollment assay.
创建时间：
2026-03-16
